163 related articles for article (PubMed ID: 11380416)
1. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.
Schultze JL; Anderson KC; Gilleece MH; Gribben JG; Nadler LM
Br J Haematol; 2001 May; 113(2):455-60. PubMed ID: 11380416
[TBL] [Abstract][Full Text] [Related]
2. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.
Coughlin CM; Vance BA; Grupp SA; Vonderheide RH
Blood; 2004 Mar; 103(6):2046-54. PubMed ID: 14630810
[TBL] [Abstract][Full Text] [Related]
3. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
4. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.
Gold JE; Ross SD; Krellenstein DJ; LaRosa F; Malamud SC; Osband ME
Eur J Cancer; 1995; 31A(5):698-708. PubMed ID: 7640041
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
[TBL] [Abstract][Full Text] [Related]
8. A novel immunotherapy to hepatocellular carcinoma: CD40-activated B lymphocytes transfected with AFPmRNA.
Wan Y; Ma X; Li X; Yi J
Med Hypotheses; 2009 Nov; 73(5):835-7. PubMed ID: 19632790
[TBL] [Abstract][Full Text] [Related]
9. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
10. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
Haining WN; Cardoso AA; Keczkemethy HL; Fleming M; Neuberg D; DeAngelo DJ; Stone RM; Galinsky I; Silverman LB; Sallan SE; Nadler LM; Guinan EC
Exp Hematol; 2005 Mar; 33(3):286-94. PubMed ID: 15730852
[TBL] [Abstract][Full Text] [Related]
11. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies.
Schultze JL; Gribben JG; Nadler LM
Curr Opin Oncol; 1998 Nov; 10(6):542-7. PubMed ID: 9818233
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
14. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
J Hematother; 1997 Jun; 6(3):253-60. PubMed ID: 9234180
[TBL] [Abstract][Full Text] [Related]
15. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens.
Kim SK; Nguyen Pham TN; Nguyen Hoang TM; Kang HK; Jin CJ; Nam JH; Chung SY; Choi SJ; Yang DH; Kim YK; Chung IJ; Kim HJ; Lee JJ
Ann Hematol; 2009 Nov; 88(11):1113-23. PubMed ID: 19277657
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study.
Schuetz F; Ehlert K; Ge Y; Schneeweiss A; Rom J; Inzkirweli N; Sohn C; Schirrmacher V; Beckhove P
Cancer Immunol Immunother; 2009 Jun; 58(6):887-900. PubMed ID: 18998129
[TBL] [Abstract][Full Text] [Related]
17. Clinical-Scale Rapid Autologous BK Virus-Specific T Cell Line Generation From Kidney Transplant Recipients With Active Viremia for Adoptive Immunotherapy.
Lamarche C; Orio J; Georges-Tobar V; Pincez T; Goupil M; Dahmani A; Carli C; Brasey A; Busque L; Delisle JS
Transplantation; 2017 Nov; 101(11):2713-2721. PubMed ID: 28230645
[TBL] [Abstract][Full Text] [Related]
18. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
20. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC.
Ivanov R; Aarts T; Hagenbeek A; Hol S; Ebeling S
Cytotherapy; 2005; 7(1):62-73. PubMed ID: 16040385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
